Type II diabetes and metformin use does not affect colorectal cancer prognosis
International Journal of Cancer · 2025
DOI: 10.1002/ijc.35266 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Mehrnoosh Shahrivar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2, Colorectal Neoplasms, Hypoglycemic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Stockholm läns landsting, Cancerfonden, Cancerföreningen i Stockholm.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Previous studies on the impact of metformin and colorectal cancer (CRC) outcomes have been limited by small size and confounding by indication, yielding inconsistent results. The aim of this study was to assess whether diabetes and pre‐diagnostic metformin use influence CRC prognosis. The study was performed using the Colorectal Cancer Data Base Sweden, a register‐linkage originating from the Swedish Colorectal Cancer Register with linkage to national health care registers and demographic registers. All adult patients diagnosed with primary non‐metastatic CRC between 2007 and 2016, treated with curative surgery, were identified and followed up from 90 days post‐surgery until December 31, 2022. Antidiabetic medication use was defined as dispensed prescription ≥6 months of use within 1 year of surgery. Type II diabetes mellitus (T2DM) patients were divided into three treatment groups (i) diet only, (ii) metformin user, and (iii) non‐metformin user. Cox regression models estimated hazard ratios (HRs) with 95% confidence intervals (CIs) for time to recurrence, CRC‐specific, and all‐cause mortality, adjusted for relevant covariates. Of 33,028 non‐metastatic CRC patients, 4539 (13.7%) had T2DM, with 1745 using metformin. A T2DM diagnosis was not associated with increased recurrence rate or CRC‐specific mortality; HR adj 0.97 (95% CI 0.89–1.06) and HR adj 0.95 (95% CI 0.87–1.05), respectively, compared with non‐diabetic patients. Furthermore, no association between T2DM, metformin use, and recurrence or CRC‐specific mortality was seen, HR adj 0.98 (95% CI 0.86–1.12) and HR adj 0.98 (95% CI 0.85–1.13), respectively. T2DM is not associated with an elevated recurrence or CRC‐specific mortality. Additionally, metformin use does not impact CRC prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
- Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
- Department of Immunology, Genetics and pathology, Uppsala University, Uppsala, Sweden.
- Department of Clinical Science and Education, Karolinska Institutet, Stockholm, Sweden.
- Department of Surgery, Stockholm, Sweden.
- Department of Pelvic Cancer, GI oncology and colorectal surgery unit, Karolinska University Hospital, Stockholm, Sweden.
ORCID-Profile: Mehrnoosh Shahrivar
Förderung
- Stockholm läns landsting
- Cancerfonden
- Cancerföreningen i Stockholm
- Insamlingsstiftelsen Cancer- och Allergifonden
Zitieren
APA
Shahrivar, M., Dietrich, C. E., Glimelius, B., Saraste, D., Martling, A., Buchli, C., & Nordenvall, C. (2025). Type II diabetes and metformin use does not affect colorectal cancer prognosis. International Journal of Cancer. https://doi.org/10.1002/ijc.35266
Vancouver
Shahrivar M, Dietrich CE, Glimelius B, Saraste D, Martling A, Buchli C, et al. Type II diabetes and metformin use does not affect colorectal cancer prognosis. International Journal of Cancer. 2025. doi:10.1002/ijc.35266
BibTeX
@article{Shahrivar2025,
author = {Shahrivar, Mehrnoosh and Dietrich, Caroline E and Glimelius, Bengt and Saraste, Deborah and Martling, Anna and Buchli, Christian and Nordenvall, Caroline},
title = {Type II diabetes and metformin use does not affect colorectal cancer prognosis},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.35266}
}
EUVIMED